Q2 2025 · 13F-HR
MPM ASSET MANAGEMENT LLCholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008430
$43.3M
Reported value
5
Positions
2025-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $29.4M | 67.9% | 4,381,062 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $6.5M | 15.0% | 682,376 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $4.7M | 10.8% | 4,309,860 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $1.6M | 3.60% | 1,121,318 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $1.2M | 2.66% | 4,809,677 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.